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Summary
Background The eﬀ ects of malaria and its treatment in the ﬁ rst trimester of pregnancy remain an area of concern. We 
aimed to assess the outcome of malaria-exposed and malaria-unexposed ﬁ rst-trimester preg nancies of women from 
the Thai–Burmese border and compare outcomes after chloroquine-based, quinine-based, or artemisinin-based 
treatments.
Methods We analysed all antenatal records of women in the ﬁ rst trimester of pregnancy attending Shoklo Malaria 
Research Unit antenatal clinics from May 12, 1986, to Oct 31, 2010. Women without malaria in pregnancy were 
compared with those who had a single episode of malaria in the ﬁ rst trimester. The association between malaria and 
miscarriage was estimated using multivariable logistic regression.
Findings Of 48 426 pregnant women, 17 613 (36%) met the inclusion criteria: 16 668 (95%) had no malaria during 
the pregnancy and 945 (5%) had a single episode in the ﬁ rst trimester. The odds of miscarriage increased in women 
with asymptomatic malaria (adjusted odds ratio 2·70, 95% CI 2·04–3·59) and symptomatic malaria (3·99, 
3·10–5·13), and were similar for Plasmodium falciparum and Plasmodium vivax. Other risk factors for miscarriage 
included smoking, maternal age, previous miscarriage, and non-malaria febrile illness. In women with malaria, 
additional risk factors for miscarriage included severe or hyperparasitaemic malaria (adjusted odds ratio 3·63, 95% 
CI 1·15–11·46) and parasitaemia (1·49, 1·25–1·78 for each ten-fold increase in parasitaemia). Higher gestational 
age at the time of infection was protective (adjusted odds ratio 0·86, 95% CI 0·81–0·91). The risk of miscarriage 
was similar for women treated with chloroquine (92 [26%] of 354), quinine (95 [27%) of 355), or artesunate (20 [31%] 
of 64; p=0·71). Adverse eﬀ ects related to antimalarial treatment were not observed.
Interpretation A single episode of falciparum or vivax malaria in the ﬁ rst trimester of pregnancy can cause miscarriage. 
No additional toxic eﬀ ects associated with artesunate treatment occurred in early pregnancy. Prospective studies 
should now be done to assess the safety and eﬃ  cacy of artemisinin combination treatments in early pregnancy.
Funding Wellcome Trust and Bill & Melinda Gates Foundation.
Introduction
Published evidence on the eﬀ ects of malaria and 
antimalarial drug exposure during the ﬁ rst trimester of 
pregnancy is scarce.1,2 This absence of data is because 
antenatal clinic services are usually unavailable in the 
rural tropics, and if they are available, women rarely 
present before the second trimester. Furthermore, 
estimation of gestational age is often imprecise, and 
pregnant women are usually excluded from drug 
studies.1,3 Artemisinin combination treatments are 
recommended by WHO for the treatment of all 
Plasmodium falciparum malaria4 except in the ﬁ rst 
trimester because results from animal studies suggest 
that artemisinins are embryotoxic. These drugs are 
selectively toxic in a dose-dependent and time-dependent 
manner to primitive fetal erythroblasts.5 Experiments 
done on animals suggest that exposure during a limited 
time window in the ﬁ rst trimester (corresponding to 
4–10 weeks of gestation or 6–12 weeks after menstruation 
in human beings6) results in fetal resorption or fetal 
loss.6–9 Limb developmental abnormalities have been 
reported in rodents, but not in primates.5 In pregnant 
cynomolgus monkeys6 no eﬀ ect on development 
(embryolethality or malformation) was reported, with 
treatment at 4 mg/kg per day of artesunate on gestational 
days 20 to 50 (ie, the “no observed adverse eﬀ ect level” 
was 4 mg/kg per day). Early red-blood-cell formation in 
human beings is spread over many days compared with 
synchronous production over 1 day in rodents and hence 
the margin of safety with short courses of artemisinin 
treatment could be greater than initially thought.9
Pregnant women are at higher risk of severe malaria 
than are non-pregnant women of the same age.10 Both 
P falciparum and Plasmodium vivax malaria reduce 
birthweight in this setting.11,12 No reliable measures for 
the prevention of malaria exist13–15 for pregnant women 
and their treatment options are limited by drug 
resistance.16
On the Thai–Burmese border the rapid spread of 
multidrug resistant P falciparum in the early 1990s17 resulted 
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in the ﬁ rst large-scale use of an artemisinin combination 
treatment (meﬂ oquine plus artesunate) for the treatment 
of uncomplicated falciparum malaria. Artesunate also 
proved safer and more eﬀ ective than intravenous quinine 
for the treatment of uncomplicated hyperparasitaemia 
(>4% infected red blood cells)18 and severe malaria.10 Once a 
drug is used inadvertent exposures during pregnancy are 
inevitable. We aimed to assess the outcome of pregnancy in 
women who had a single episode of malaria in the ﬁ rst 
trimester (and no further episode later in pregnancy) 
compared with women in the ﬁ rst trimester of pregnancy 
who had no malaria. Additionally, we assessed the outcome 
of pregnancy after treatment with chloroquine-based, 
quinine-based, or artesunate-based antimalarials, for ﬁ rst 
trimester infection.
Methods
Study area and population
The Shoklo Malaria Research Unit (SMRU) is situated 
on the northwestern border of Thailand. Malaria 
transmission is low and seasonal in this region. Pregnant 
women have been encouraged to attend SMRU clinics 
providing antenatal care for the early detection and 
treatment of malaria since 1986 for refugees and since 
1998 for migrants. Ethical approval for this audit of 
hospital records was given by the Oxford Tropical 
Research Ethics Committee (OXTREC 28-09). Data on 
ﬁ rst-trimester malaria from some of the same records 
have been published previously.12,19–21
Procedures
Women were encouraged to attend as soon as they were 
aware of their pregnancy. More than 90% of pregnant 
women in the camps for displaced persons where SMRU 
operates (current population 55 000) have attended 
antenatal clinics for regular malaria screening.12 At the 
ﬁ rst consultation, an obstetric and medical history was 
recorded, and a detailed clinical examination was done. 
History of malaria during pregnancy and information 
on date, place, malaria species, parasitaemia, and drug 
treatment was recorded. Information on smoking was 
gathered routinely from July, 1997. History of miscarriage 
was divided into none, a single previous miscarriage, 
and two or more miscarriages.22 At each weekly visit a 
ﬁ nger-prick blood sample was examined for malaria 
parasites by trained microscopists. Haematocrit was 
measured every 2 weeks. Women were also encouraged 
to attend the antenatal clinic at any time if they felt 
unwell. Axillary or aural temperatures were recorded 
routinely. Although detailed diagnostics were available 
for some women with fevers (≥37∙5°C) caused by 
diseases other than malaria,23 the diagnosis of non-
malaria febrile illness relied mainly on clinical ﬁ ndings. 
Rates of HIV and syphilis were very low in the study 
population24 and have not been included in this analysis.
Severity of malaria was categorised into three groups: 
uncomplicated malaria; hyperparasitaemic malaria 
(parasitaemia ≥4% without signs of severity or evidence 
of vital-organ dysfunction); and severe malaria (signs of 
severity or severe organ dysfunction). Symptomatic 
malaria was deﬁ ned as parasitaemia and a history of fever 
in the past 48 h or a measured axillary or aural temperature 
of 37∙5°C or more.25 Asymptomatic malaria was deﬁ ned 
as slide-conﬁ rmed malaria with no history of fever in the 
previous 48 h and a temperature of less than 37∙5°C. No 
presumptive treatment of malaria was given. Severe 
anaemia was deﬁ ned as a haematocrit less than 20%.
Figure: Study proﬁ le
945 had single episode of first-trimester malaria
37 excluded
       10 mixed
         8 Plasmodium malariae or Plasmodium ovale
      19 unknown species
908 had first-trimester Plasmodium falciparum 
          or Plasmodium vivax infections
          595 delivered
          313 miscarried
105 had signs of pregnancy loss
  30 had treatment with antimalarials other than 
        chloroquine, quinine, or artesunate
        29 mefloquine monotherapy 
           1 unknown
773 had first-trimester P falciparum or P vivax
         infection and were treated with choloroquine, 
         quinine, or artesunate
         566 delivered (262 chloroquine, 260 quinine, 
                  44 artesunate)
         207 miscarried (92 chloroquine, 95 quinine, 
                 20 artesunate)
174 infants were not a liveborn, normal, 
         singleton weighed <72 h after birth
392 had first-trimester P falciparum or P vivax, 
          valid birthweight, and were treated with 
          antimalarials
         192 chloroquine
         171 quinine
          29 artesunate
16 668 had no malaria
      13 470 delivered
      3198 miscarried
17 613 had no or only one episode of first-trimester malaria
              14 086 delivered
                  3527 miscarried
48 426 women were registered
23 137 had no malaria and enrolled after first trimester of pregnancy
  2568 had unknown pregnancy outcome
  2027 were enrolled at first trimester of pregnancy but had a malaria 
             episode in the second or third trimester
  1712 had no valid estimate of gestational age available
 1369 had more than one episode of malaria
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Patients with vivax malaria were treated with oral 
chloroquine 10 mg base per kg on day 0, 10 mg base per 
kg on day 1, and 5 mg base per kg on day 2. Patients 
with falciparum malaria were treated with oral quinine 
10 mg salt per kg three times a day for 7 days or 
artesunate (outside the ﬁ rst trimester), usually 2 mg/kg 
per day for 7 days (total dose 10–16 mg/kg). Since 2007, 
clindamycin (5 mg/kg three times a day for 7 days) was 
added to quinine as ﬁ rst-line treatment in the ﬁ rst 
trimester. Artesunate was prescribed in the ﬁ rst 
trimester for quinine treatment failures, uncomplicated 
hyper para sitaemia, or severe malaria,4 although before 
1993 these patients were treated with intravenous 
quinine. Women also received thiamine (vitamin B1, 
100 mg a day) to prevent infant mortality from beri-beri, 
and ferrous sulphate and folic acid at prophylactic doses 
(200 mg a day and 5 mg a week, respectively) or 
treatment doses (200 mg three times a day and 5 mg a 
day, respectively). Delivery with the assistance of trained 
midwives in the SMRU delivery unit was encouraged, 
but home birth with a traditional birth attendant was 
still practised. All newborns, including those born at 
home, were examined by trained midwives and were 
weighed with Salter scales (Salter, Birmingham, UK; 
accurate to 50 g).26
First trimester was deﬁ ned as an estimated gestational 
age less than 14 weeks. Methods to estimate gestational 
age included ultrasound,27 the Dubowitz newborn 
assessment,28 a fundal height formula validated for this 
population,29 or last menstrual period. Ultrasound at 
7–13 weeks can measure gestational age to within 3 days, 
but scans done later, 14–22 weeks, decline in accuracy and 
can measure gestational age to within 7 days.27 The 
Dubowitz examination in term infants can measure 
gestational age to within 14 days of the examination,28 and 
the fundal height formula varies in accuracy from –16 to 
14 days.29 All infants had a surface examination at delivery 
by midwives using a standardised newborn head-to-toe 
examination, with cardiovascular examination routinely 
done since 2006 and all major abnormalities recorded and 
veriﬁ ed by a physician.
We reviewed all records of pregnant women attending 
the antenatal clinic until delivery from May 12, 1986, to 
Oct 31, 2010. The primary objective of the investigation 
was to assess the eﬀ ects of malaria on pregnancy 
outcomes in the ﬁ rst trimester, and to compare the eﬀ ects 
of diﬀ erent antimalarial drugs. To avoid the confounding 
eﬀ ects of multiple malaria episodes and exposure to 
diﬀ erent antimalarial drugs during pregnancy, we 
selected women who began attending the antenatal clinic 
in their ﬁ rst trimester and if they had malaria (ie, only 
those with a single ﬁ rst-trimester episode). Women with 
no valid estimate of gestation, who had malaria in the 
second or third trimesters, or who had an unknown 
outcome were excluded from this analysis.
Analysis of birthweight was restricted to liveborn, 
congenitally normal, singleton infants weighed in the 
ﬁ rst 72 h of life. Miscarriage was deﬁ ned as a pregnancy 
ending before 28 weeks, estimated gestational age. 
Termination of pregnancy was not available in this 
remote area. Stillbirth was a delivery from 28 weeks or 
an infant with a birthweight of 800 g or more in which 
the infant displayed no sign of life (gasping, muscular 
activity, cardiac activity). The 28-week estimated 
gestational age, rather than the current WHO 22-week 
cut-oﬀ  for estimated gestational age was chosen, because 
no infant respiratory support was available in the clinics. 
Preterm births were deliveries before 37 weeks estimated 
gestational age. A non-viable conceptus was deﬁ ned 
either by ultrasound examination (absent fetal heart 
beat, anembryonic gestation, retained products of 
conception, ectopic pregnancy, hydatidiform mole) or 
No malaria in 
pregnancy (16 668)
First trimester 
malaria (945)
p value
Age, years* 27 (7; 13–52) 26 (7; 13–45) <0·0001
Teenagers, <20  years of age* 2416 (15%) 189 (20%) <0·0001
Number of pregnancies† 3 (2–5; 1–17) 3 (1–5; 1–13) 0·0171
Parity‡ 2 (1–3; 0–13) 1 (0–3; 0–10) 0·0002
Women in their ﬁ rst pregnancy† 3369 (20%) 257 (27%) <0·0001
Smokers§ 4095 (30%) 225 (37%) 0·0002
Previous miscarriage¶ 4759 (29%) 315 (33%) 0·002
Smoking by age category
13–20 years 3587 (22%) 280 (30%) <0·0001
21–25 years 4154 (25%) 226 (24%) 0·5098
26–30 years 4230 (25%) 199 (21%) 0·0029
≥31 years 4696 (28%) 240 (25%) 0·0690
Non-malaria febrile illness* 293 (2%) 15 (2%) 0·7855
Antimalarial Treatment
Chloroquine NA 429 (45%) ··
Quinine NA 390 (41%) ··
Artemisinin derviative NA 92 (10%) ··
Meﬂ oquine NA 32 (3%) ··
Other or unknown NA 2 (<1%) ··
Median number of antenatal consultations for 
women with delivery
26 (13–29; 1–40) 24 (4–26; 1–37) <0·0001
Miscarriage 3198 (19%) 329 (35%) <0·0001
Data are mean (SD; range), median (IQR; range), or number (%). NA=not applicable. *Data missing for one patient in 
no malaria group. †Data missing for 27 patients in the no malaria group and one patient in malaria group. ‡Data 
missing for 36 patients in the no malaria group and one patient in the malaria group. §Data missing for 2887 patients 
in the no malaria group and 336 patients in the malaria group. ¶Data missing for 104 patients in the no malaria group 
and three patients in the malaria group.
Table 1: Demographic characteristics
Chloroquine Quinine Artesunate
All women* 25 (0–169; 16–44; 92) 18 (1–172; 7–42; 95) 47 (0–91; 15–87; 20)
Ultrasound conﬁ rmed 
gestation†
25 (0–101; 14–42; 42) 19 (1–172; 7–42; 27) 37·5 (4–73; 10–51; 8)
Data are median (range; IQR; number of women). *p value for chloroquine versus quinine=0·041; p value for 
chloroquine versus artesunate=0·061; p value for quinine versus artesunate=0·027. †p value for chloroquine versus 
quinine=0·526; p value for chloroquine versus artesunate=0·450; p value for quinine versus artesunate=0·479.
Table 2: Interval in days from treatment of malaria to date of miscarriage according to treatment group
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clinically (when ultrasound was not available) by 
signiﬁ cant vaginal bleeding in early pregnancy, open 
cervix on examination, passage of products of con-
ception, or a negative pregnancy test. The date of 
expulsion of the uterine contents either spontaneously 
or by the use of medical or surgical intervention was 
taken as the date of miscarriage. The interval from 
treatment to date of miscarriage was not used in primary 
analysis because the capacity to diagnose non-viability 
and remove the uterine contents changed over time. 
Some women discontinued antenatal care before the 
outcome of pregnancy was known, usually because they 
left the study area.
Statistical analysis
Data were analysed with SPSS (version 14∙0) and STATA 
(version 11). Comparisons were made using the Student’s 
t test or Mann-Whitney U test. Categorical variables were 
compared using the χ² test or Fisher’s exact test. To assess 
the role of malaria as a risk factor for miscarriage, malaria 
(symptomatic or asymptomatic) versus no malaria, 
number of pregnancies (multiple pregnancies vs ﬁ rst 
pregnancy), smoking status (yes or no), age of mother 
(13–20, 21–25, 26–30, ≥31 years), number of miscarriages 
(none, one, or two or more), and non-malaria febrile 
illness in the ﬁ rst trimester were examined initially with 
univariable logistic regression analysis with miscarriage 
as the outcome variable. We used multivariable logistic 
regression analysis to estimate the odds for miscarriage 
associated with malaria after accounting for age, smoking, 
women in their ﬁ rst  pregnancy, number of previous 
miscarriages, and non-malaria febrile illness. Analyses 
were also repeated with adjustment for year of enrolment 
and the results were unchanged (data not shown). 
Adjusted population attributable fractions of miscarriage 
due to symptomatic and asymptomatic malaria, and 
falciparum and vivax malaria, were calculated using the 
aﬂ ogit module for STATA.30
To distinguish the eﬀ ects of P falciparum and P vivax 
on the risk of miscarriage, and to estimate the 
associations between malaria severity, baseline log 
parasitaemia, and the risk of miscarriage, we did a 
subgroup analysis of women with malaria during the 
ﬁ rst trimester and excluded women with mixed 
Miscarriage (3527) Delivery (14 086) Unadjusted odds ratio Adjusted odds ratio* Population 
attributable 
fraction
Malaria symptoms†
No malaria 92% (3198) 97% (13470) Reference group Reference group ··
Asymptomatic malaria 3% (104) 2% (213) 2·06 (1·62–2·61; p<0·0001) 2·70 (2·04–3·59; p<0·0001) 1·4% (1·0–1·9)
Symptomatic malaria 5% (157) 1% (172) 3·84 (3·09–4·79; p<0·0001) 3·99 (3·10–5·13; p<0·0001) 2·6% (2·1–3·1)
Pregnancy
Women in their ﬁ rst pregnancy 15% (537) 22% (3089) Reference group Reference group ··
Women who have had more 
than one pregnancy‡
85% (2986) 78% (10973) 1·57 (1·42–1·73; p<0·001) ··§ ··
Smoking¶
Non-smoker 62% (1817) 72% (8253) Reference group Reference group ··
Smoker 38% (1129) 28% (3191) 1·61 (1·48–1·75; p<0·0001) 1·26 (1·15–1·38; p<0·0001) 5·8% (3·4–8·1)
Age||
13–20 years 16% (558) 23% (3309) Reference group Reference group ··
21–25 years 19% (668) 26% (3712) 1·07 (0·94–1·21; p=0·295) 0·97 (0·84–1·11; p=0·627) ··
26–30 years 23% (825) 26% (3604) 1·36 (1·21–1·53; p<0·0001) 1·21 (1·06–1·39; p=0·005) 3·3% (1·0–5·5)
≥31 years 42% (1476) 25% (3460) 2·53 (2·27–2·82; p<0·0001) 2·16 (1·90–2·46; p<0·0001) 18·9% (15·9–21·8)
Number of previous miscarriages**
None 61% (2133) 74% (10298) Reference group Reference group ··
One 24% (857) 19% (2671) 1·55 (1·42–1·69; p<0·0001) 1·31 (1·18–1·45; p<0·0001) 4·4% (2·7–6·1)
Two or more 15% (518) 7% (1029) 2·43 (2·17–2·73; p<0·0001) 1·89 (1·65–2·17; p<0·0001) 5·3% (4·0–6·5)
Non-malaria febrile illness in the ﬁ rst trimester
No 96% (3402) 99% (13903) Reference group Reference group ··
Yes 4% (125) 1% (183) 2·79 (2·22–3·52; p<0·0001) 3·00 (2·34–3·84; p<0·0001) 2·1% (1·6–2·7)
Data are number (%), unadjusted or adjusted odds ratio (95% CI), or population attributable fraction (95% CI). *n=14 190 (results unchanged if smoking variable excluded 
from multivariable logistic regression model [n=17 207]). †Data missing for 68 patients in the miscarriage group and 231 patients in the delivery group. ‡Data missing for 
four patients in the miscarriage group and 24 patients in the delivery group. §Highly collinear with number of previous miscarriages since women in their ﬁ rst pregnancy 
cannot have a previous miscarriage; estimated adjusted odds ratios for the other variables were unchanged whether parity or number of previous miscarriages were 
adjusted for or not. ¶Data missing for 581 patients missing in the miscarriage group and 2642 in the delivery group. ||Data missing for one patient in the miscarriage 
group. **Data missing for 19 patients in the miscarriage group and 88 patients in the delivery group.
Table 3: Risk factors associated with miscarriage in women with either no malaria or a single malaria episode in the ﬁ rst trimester and known outcomes
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infections (ten), episodes of Plasmodium malariae or 
Plasmodium ovale (eight), or unknown species (19). Birth 
outcomes were also compared between women treated 
with chloroquine, quinine, and artesunate, and women 
who had no malaria during pregnancy. A one-way 
ANOVA was used to compare mean estimated 
gestational age at birth and mean birthweight across the 
groups, and the χ² test was used to compare the 
proportion of stillbirths and congenital abnormalities.
Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had 
full access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for 
publication. 
Results
Of 17 613 eligible women 15 735 (89%) presented to the 
SMRU clinic for antenatal care because they had a normal 
pregnancy (ﬁ gure); others attended the clinic with signs 
of pregnancy loss (1196 [7%]), symptomatic malaria 
(microscopy conﬁ rmed; 280 [2%]), symptoms of illness 
(not malaria; 398 [2%]), or both symptomatic malaria and 
symptoms of other illness (four [<1%]). The proportions 
of teenagers, women in their ﬁ rst preg nancies, smokers, 
and those with a history of previous miscarriage, were 
Miscarriage (313) Delivery (595) Unadjusted odds ratio (95% 
CI; p value) 
Adjusted odds ratio 
(95% CI; p value)* 
Malaria symptoms†
Asymptomatic 39% (100) 56% (211) Reference group Reference group
Symptomatic 61% (154) 44% (169) 1·92 (1·39–2·66; p=0·0001) 1·42 (0·95–2·14; p=0·089)
Severity of malaria‡
Uncomplicated 95% (297) 98% (580) Reference group Reference group
Severe or hyperparasitaemic 5% (14) 2% (10) 2·73 (1·20–6·23; p=0·017) 3·63 (1·15–11·46; p=0·028)
Species
Plasmodium falciparum 52% (163) 56% (333) Reference group Not included
Plasmodium vivax 48% (150) 44% (262) 1·17 (0·89–1·54; p=0·263) Not included
Pregnancy
Women in their ﬁ rst pregnancy 25% (78) 28% (169) Reference group Not included
Women who have had more than 
one pregnancy§
75% (235) 72% (425) 1·20 (0·88–1·64; p=0·256) Not included
Smoking¶
Non-smoker 51% (122) 71% (252) Reference group Reference group
Smoker 49% (118) 29% (104) 2·34 (1·67–3·30; p<0·0001) 2·08 (1·43–3·02; p=0·0007)
Age
13–20 years 27% (84) 31% (187) Reference group Reference group
21–25 years 17% (54) 28% (166) 0·72 (0·49–1·08; p=0·114) 0·78 (0·47–1·29; p=0·333)
26–30 years 21% (66) 20% (120) 1·22 (0·82–1·82; p=0·316) 1·30 (0·78–2·15; p=0·318)
≥31 years 35% (109) 21% (122) 1·99 (1·38–2·86; p=0·0002) 1·85 (1·16–2·96; p=0·010)
Number of previous miscarriages||
None 62% (194) 68% (406) Reference group Not included
One 25% (79) 21% (126) 1·31 (0·94–1·82; p=0·106) Not included
Two or more 12% (38) 10% (62) 1·28 (0·83–1·99; p=0·266) Not included
Non-malaria febrile illness in the ﬁ rst trimester
No 97% (305) 99% (590) Reference group Not included
Yes 3% (8) 1% (5) 3·10 (1·00–9·54; p=0·049)
Calculated estimated gestational age at 
malaria episode, weeks (median [IQR])
8·0 (5·7–10·5)†† 10·2 (7·6–12·3)†† 0·88 (0·85–0·92; p<0·0001) 0·86 (0·81–0·91; p<0·0001)
Parasitaemia, μL (geometric mean 
[95% CI; number of women])**
1020 (726–1432; 262)‡‡ 300 (238–378; 413)‡‡ 1·52 (1·32–1·75; p<0·0001)§§ 1·49 (1·25–1·78; p<0·0001)§§
Data are unadjusted or adjusted odds ratio (95% CI). *The variables malaria (asymptomatic or symptomatic), severity of malaria, and parasitaemia were ﬁ tted in separate 
models because of collinearity, with each model adjusting for age, smoking, and calculated estimated gestational age at malaria episode. †Data missing for 59 patients in the 
miscarriage group and 215 in the delivery group. ‡Data missing for two patients in the miscarriage group and ﬁ ve in the delivery group. §Data missing for one patient in the 
delivery group. ¶Data missing for 73 patients in the miscarriage group and 239 in the delivery group. ||Data missing for two patients in the miscarriage group and one in the 
delivery group. **Data missing for 51 patients in the miscarriage group and 182 in the delivery group. ††Data are median (IQR). ‡‡Data are geometric mean (95% CI; number 
of women). §§Relative change in odds for miscarriage associated with a ten-fold increase in parasitaemia.
Table 4: Risk factors associated with miscarriage in women with a single ﬁ rst-trimester episode of Plasmodium vivax or Plasmodium falciparum
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higher in women with malaria compared with those with 
no malaria (table 1). Smoking increased with age. Slight 
demographic diﬀ erences existed between the 
30 813 excluded and 17 613 included women; excluded 
women were slightly younger, with more teenagers and 
women in their ﬁ rst pregnancy (appendix p 1). Women 
with unknown pregnancy outcomes (2376) were slightly 
younger, more likely to be in their ﬁ rst pregnancy, and to 
have malaria within the ﬁ rst trimester than were women 
with known pregnancy outcomes (17 613). The distribution 
of anti malarial treatments was similar in the two groups 
(appendix p 1).
The interval in days from the start of treatment of 
malaria to the date of the miscarriage was examined for 
each antimalarial treatment group (table 2). In 
pregnancies dated with the optimum technique, 
ultrasound, no signiﬁ cant diﬀ erence was reported. The 
gestation at the start of diagnosis, equivalent to the date 
of treatment, was used for the following part of the 
analysis.
Of 17 613 pregnant women, 14 086 (80%) delivered and 
3527 (20%) miscarried. Severe anaemia in the ﬁ rst 
trimester in this cohort was infrequent (18 [<1%] of 
16 483; 16 in women with malaria, and two in the non-
malaria group), and it has not been included in further 
analysis. Signiﬁ cant risk factors for miscarriage included 
malaria (asymptomatic or symptomatic), having had 
more than one pregnancy, smoking, older maternal age, 
number of previous miscarriages, and non-malaria 
febrile illness in the ﬁ rst trimester (table 3). Since women 
in their ﬁ rst pregnancy cannot have had a previous mis-
carriage, we included number of previous miscarriages 
(and excluded the variable women who had had more 
than one pregnancy) in the multivariable logistic 
regression analyses. The results were unchanged if we 
adjusted for number of pregnancies instead of number 
of previous miscarriages. To ensure that exclusion of 
women without smoking data did not bias the results, we 
repeated the analyses with only the exposure variables: 
malaria, maternal age, number of miscarriages, and non-
malaria febrile illness, in the logistic regression model. 
The results were unchanged. The highest odds for 
miscarriage were for women with symptomatic malaria 
compared with women with no malaria (table 3). 
Importantly, asymptomatic malaria was also associated 
with miscarriage. The population attributable fraction of 
miscarriage due to asymptomatic malaria was lower than 
symptomatic malaria, and for non-malaria febrile 
illness.
Of 945 single episodes of malaria in the ﬁ rst trimester 
496 were P falciparum only, 412 P vivax only, ten were 
mixed infections, eight P malariae or P ovale only, and 
19 were not speciated (ﬁ gure). Among the 908 women 
with P falciparum or P vivax monoinfections 595 (66%) 
women delivered and 313 (34%) miscarried. Maternal 
age, smoking history, number of previous miscarriages, 
estimated gestational age at the time of malaria episode, 
and parasitaemia were all signiﬁ cantly associated with 
miscarriage (515 women in the ﬁ nal model). The odds of 
miscarriage nearly doubled when maternal age was 
31 years or older, and were twice as high among smokers 
(table 4). The odds of miscarriage increased 50% per ten-
fold increase in parasitaemia. Only 24 women had 
uncomplicated hyperparasitaemia or severe malaria and 
this group had a higher odds of miscarriage than did 
those with uncomplicated malaria (adjusted odds 
ratio 3∙63, 95% CI 1∙15–11∙46). The risks of miscarriage 
were similar in women with P vivax or P falciparum 
(table 4). Analysis of data from all women and adjustment 
for maternal age, previous miscarriages, smoking, and 
non-malaria febrile illness showed that the odds of 
miscarriage were about three times higher for women 
infected with P falciparum (adjusted odds ratio 2∙7, 
95% CI 2∙1–3∙4) or P vivax (3∙1, 2∙4–3∙9) malaria than 
they were for women with no malaria. The population 
attributable fractions of miscarriage due to P vivax (2∙2%, 
95% CI 1∙6–2∙8) and P falciparum malaria (1∙9%, 
1∙3–2∙4) were similar. The proportion of miscarriage in 
pregnancies unaﬀ ected by malaria (19% [3198]) was 
similar to that seen in developed countries (10–20%), as 
are the associations with previous miscarriage, older 
maternal age, and smoking (table 3).31 
Single course treatments were with chloroquine (354), 
quinine (355), or artesunate (64). Intentional treatment 
with artemisinins was predominantly monotherapy 
(21 of 30 women) whereas inadvertent treatment 
(34 women) was all with an artemisinin combination 
treatment (table 5).
Of 773 women treated for malaria, 566 (73%) delivered 
and 207 (27%) miscarried: 92 (26%) of 354 after treatment 
with chloroquine, 95 (27%) of 355 after treatment with 
quinine, and 20 (31%) of 64 after treatment with artesunate 
(p=0∙71), despite the use of artesunate for high-risk 
groups (treatment failures and uncomplicated hyper-
parasitaemia or severe malaria). Among 34 women in-
advertently given an artemisinin combination treatment, 
Delivery Miscarriage Total
Intentional treatment ·· ·· 30
Artesunate monotherapy 10 (59%) 7 (41%) ··
Artesunate and clindamycin 6 (67%) 3 (33%) ··
Artesunate (rescue after quinine) 2 (50%) 2 (50%) ··
Inadvertent treatment ·· ·· 34
Artesunate and atovaquone-proguanil 1 (100%) 0 ··
Artesunate and doxycycline 1 (100%) 0 ··
Artemether-lumefantrine 1 (100%) 0 ··
Dihydroartemisinin and piperaquine 2 (100%) 0 ··
Artesunate and meﬂ oquine 21 (72%) 8 (28%) ··
Total 44 (69%) 20 (31%) 64
Data are number (%)
Table 5: Artemisinin treatments given to women with a single episode of malaria in the ﬁ rst trimester of 
pregnancy with a known pregnancy outcome
See Online for appendix
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eight (24%) misscarried. This percentage was signiﬁ cantly 
lower than for miscarriage in women treated for 
uncomplicated hyperparasitaemia or severe malaria (nine 
[56%] of 16; p=0·030), but did not diﬀ er signiﬁ cantly 
when compared with miscarriage after intentional treat-
ment of uncomplicated malaria (three [21%] of 14; 
p=0·072). Women with severe malaria or uncomplicated 
hyperparasitaemia usually received 16 mg/kg total dose of 
artesunate over 7 days whereas women with uncomplicated 
malaria received 12–14 mg/kg over 7 days.
Drug exposures between 6 and 12 weeks, gestation were 
investigated further: miscarriage proportions were 40% 
(ten of 25) for women treated with artesunate compared 
with 26% (51 of 193; p=0∙162) for quinine and 30% 
(64 of 215; p=0∙360) for chloroquine. After adjusting for 
the severity of P falciparum infection the risk for 
miscarriage in recipients of artesunate and quinine was 
not signiﬁ cantly diﬀ erent (adjusted odds ratio 1∙22, 
95% CI 0∙45–3∙27; p=0∙70). Allowing for a plus or minus 
14-day error on estimation of gestational age and so 
broadening the exposure window to between 4 weeks and 
less than 14 weeks, the miscarriage proportions were 34% 
(17 of 50) for women who received artesunate compared 
with 26% (83 of 323; p=0∙232) for quinine and 26% 
(87 of 329; p=0∙307) for chloroquine. Adverse eﬀ ects 
related to treatment were not seen with quinine, 
chloroquine, or artesunate, although the numbers 
available for the artesunate group were small.
A single episode of malaria in the ﬁ rst trimester did not 
predispose to later stillbirth (table 6). The birthweight of 
liveborn infants in the non-malaria group (mean 2970 g 
[SD 451; range 900–5080]; n=11204) was not signiﬁ cantly 
higher than in the malaria group (2940 g [471; 780–4300]; 
n=392; p=0∙217). Birthweights after ﬁ rst-trimester 
P falciparum (2962 g [SD 477; range 780–4300]; n=200) 
and P vivax infections (2917 g [465; 790–4130]; n=192; 
p=0∙341) were similar. More infants born to mothers who 
had ﬁ rst-trimester malaria than those born to mothers 
without malaria were either never weighed or were 
weighed after 72 h (table 6). The overall proportion of 
congenital abnormalities did not diﬀ er signiﬁ cantly 
between groups (table 6, appendix p 2).
Discussion
This study is the largest to assess the eﬀ ects of malaria 
and its treatment in the ﬁ rst trimester of pregnancy 
(panel). The study was undertaken in a remote rural area, 
in a community exposed to low seasonal transmission of 
P falciparum and P vivax. Despite the terrain, antenatal 
clinic attendance was very high. Malaria in pregnancy is 
a major cause of maternal mortality and low birthweight, 
which predisposes to neonatal mortality. Drug safety 
concerns still restrict the recommended treatment for 
falciparum malaria in the ﬁ rst trimester to a 7 day course 
of quinine—a poorly tolerated, poorly adhered to, and 
therefore ineﬀ ective treatment.
Malaria in the ﬁ rst trimester was associated with 
miscarriage, and the association is likely to be causal. Risk 
of miscarriage was higher for women with symptomatic 
and asymptomatic malaria than it was for women who did 
not have malaria in the ﬁ rst trimester (table 3). The odds 
were similar with P falciparum and P vivax. Thus both 
vivax and falciparum malaria contribute signiﬁ cantly to 
avoidable fetal and infant death. This ﬁ nding emphasises 
the importance of early detection of malaria and prompt 
eﬀ ective treatment for all pregnant women. The 
comparably increased odds of miscarriage in non-malaria 
febrile illnesses suggest a pathogenic role of fever and 
proinﬂ ammatory responses,32 while the increased risk of 
abortion with asymptomatic malaria suggests a more 
malaria-speciﬁ c pathological process.
A single successfully treated episode of malaria in the 
ﬁ rst trimester without later infection did not signiﬁ cantly 
aﬀ ect birthweight. This suggests either a minimal eﬀ ect 
of ﬁ rst-trimester infections on fetal growth or an eﬃ  cient 
recovery during the remaining gestation. Later in 
No malaria, no treatment 
(13 470)
Chloroquine (262) Quinine (260) Artesunate (44) p value 
Stillbirths* 153/13158 (1%) 3/254 (1%) 7/257 (3%) 1/44 (2%) 0·131
Male† 6718/13 315 (50%) 146/259 (56%) 144/253 (57%) 23/44 (52%) 0·055
Congenital abnormality‡ 198/13 339 (1%) 1/260 (<1%) 2/258 (1%) 2/44 (4·5) 0·117
Twins 134/13 470 (1%) 0 1/260 (<1%) 1/44 (2%) 0·225
Estimated gestational age at birth, 
weeks
39·0 (1·8 [28·0–45·5]) 38·8 (2·2 [28·0–44·0]) 38·9 (2·1 [28·3–42·9]) 38·9 (1·8 [32·6–41·4]) 0·194
Birthweight not measured§ 390/13 470 (3%) 13/262 (5%) 19/260 (7%) 4/44 (9%) <0·0001
Liveborn normal singleton infants§
Birthweight measured <72 h 11 204/12 204 (89%) 192/239 (80%) 171/233 (73%) 29/38 (76%) <0·0001
Birthweight, g 2970 (451 [900–5080]) 2917 (465 [790–4130]) 2950 (488 [780–4300]) 3035 (408 [2250–3900]) 0·318
Data are number (%) or mean (SD [range]). *Data missing for 312 patients in the no malaria, no treatment group, eight in the  chloroquine group, and three in the quinine 
group. †Data missing for 155 patients in the no malaria, no treatment group, three in the chloroquine group, and seven in the quinine group. ‡Data missing for 131 patients 
in no malaria, no treatment group, two in the chloroquine group, and two in the quinine group. §Weight measured and completed within 72 h of birth.
Table 6: Neonatal outcomes of pregnancies followed up from the ﬁ rst trimester by antimalarial treatment group
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pregnancy, the importance of malaria-speciﬁ c pathogenic 
processes such as those related to placental cytoadherence 
presumably increases. Nevertheless, these ﬁ ndings have 
serious implications for malaria treatment and prevention 
policies, which currently ignore the ﬁ rst trimester. Early 
detection and treatment will reduce the eﬀ ects of 
symptomatic malaria on miscarriage but only prevention 
can eliminate the increased risk of miscarriage in women 
with asymptomatic disease. Preventive options are 
limited, especially in terms of eﬀ ective and safe 
prophylaxis. Symptomatic malaria infections are less 
common in areas of high transmission, where women 
have greater immunity than in areas of low transmission, 
but the increased risk of miscarriage with asymptomatic 
malaria is of major concern because the prevalence of 
asymptomatic malaria parasitaemia in such areas is very 
high. Prospective studies in high-transmission settings 
are needed to assess these risks.
Our analysis could not account for several factors: 
inherent errors in assessments of gestational age, 
pregnancy intervals, use of contraceptives (low uptake in 
this population), the fact that heavy bleeding can be 
reported as miscarriage, the possibility of confounding 
bacterial vaginosis, and environmental factors such as 
DDT (dichlorodiphenyltrichloroethane) exposure.33
Data on the safety of artemisinin derivatives are 
reassuring. We did not record high rates of fetal 
resorption, which have been reported in animal studies.6–9 
Globally, 333 ﬁ rst-trimester exposures to artemisinin 
derivatives have been reported with known pregnancy 
outcomes: Deen and colleagues34 reported 77 pregnancies 
with an unknown malaria status and Manyando and 
colleagues35 reported 106; Adam and colleagues36 reported 
62 pregnancies with a conﬁ rmed malaria diagnosis and 
we have reported 44. No signiﬁ cant adverse eﬀ ects have 
been recorded. Artemisinin derivatives were not used 
routinely in early pregnancy in our study sites. 
Miscarriage rates in the 24 ﬁ rst-trimester episodes of 
hyperparasitaemia or severe malaria were high but 
artesunate did not result in higher rates of miscarriage 
than did quinine. Antimalarials, especially artemisinin 
derivatives in this cohort, were not associated with 
miscarriage after controlling for maternal and malaria 
characteristics. Birth outcomes did not diﬀ er signiﬁ cantly 
after ﬁ rst-trimester antimalarial treatment with artesunate 
compared with the other antimalarials, quinine and 
chloroquine. No signiﬁ cant excess of malformations was 
reported. Overall, these results suggest that the adverse 
eﬀ ects of malaria in the ﬁ rst trimester substantially 
outweigh any adverse eﬀ ects of its treatment. Nevertheless, 
further information, preferably from a randomised trial 
of artemisinin combination treatment in the ﬁ rst 
trimester, is needed before deﬁ nitive statements on safety 
can be made.
This study shows that, in the context of ready access to 
eﬀ ective treatment, the adverse eﬀ ects of falciparum and 
vivax malaria are similar and substantial in early 
pregnancy. Malaria control measures must be directed 
against all malarias (including asymptomatic infections). 
The time has come to reassess the treatment of malaria 
in early pregnancy.
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